ArticleInternational journal of clinical and experimental pathology2018
Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.Cancers · 2021Review
- Article
- Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden.F1000Research · 2021Article
- Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the effects and signaling pathways involved in both HGF-mediated regulation of PARP-1 expression and the invasion ability of ovarian cancer cells. Using a transwell assay, the invasiveness of SKOV-3 cells was tested by incubating them with increasing concentrations of HGF. The relative expression levels of PARP-1 after HGF treatment were analyzed by Real-Time PCR and western blotting. SKOV3 cells were transfected with either negative control siRNA or PARP-1 siRNA, and were divided into different groups as follows: control group; HGF group; PARP-siRNA group; HGF+PARP-siRNA group; NC-siRNA group; and HGF+NC-siRNA group. Western blotting was employed to measure the expression of PARP-1 in the different groups. Transwell tests were used to examine invasiveness. ELISA was applied to measure MMP-2 expression. HGF promotes cell invasion in a concentration- and time-dependent manner in SKOV-3 cells. The expression levels of PARP-1 increased after administration of 40 ng/ml HGF for 24 h. The expression of PARP-1 in the PARP1-siRNA group was lower compared with that in the NC-siRNA group (P < 0.05); PARP1-siRNA transfection significantly reduced the impact of HGF on invasiveness and MMP-2 expression in SKOV-3 cells. HGF promotes the invasiveness and metastasis of ovarian cancer cells. This effect could be related to the induction of increased expression levels of MMP-2 mediated by PARP-1.
Indexed as
Identifiers
31949706PMC6962858W3027631273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.